News

Martin spoke about the barriers standing in the way of CPAP adherence in women with sleep apnea at SLEEP 2024.

This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.

Data collected from parallel online surveys revealed notable differences in IgA nephropathy treatment among patients and nephrologists from the US, EU5, Japan, and China.

A post-hoc analysis of the ARCADIA program provides insight into the speed of itch relief onset observed with nemolizumab among patients with moderate-to-severe atopic dermatitis.

At SLEEP 2024, Hartung discussed FloraWorks’ study finding patients on CBN had greater improvements in sleep quality than melatonin, but the difference was not significant.

Michael Freeman joins Veeral Sheth, MD to discuss the history of Ocutrx, its OcuLenz and OR-Bot products, and what he envisions in the next decade at the company.

In his RAD 2024 talk, Bissonnette presented recent data on 4 topical drugs for atopic dermatitis, including crisaborole and ruxolitinib.

A post-hoc analysis of the phase 2b ORIGIN study highlights atacicept’s impact on hematuria, with more patients achieving improvement and resolution at 36 weeks than those on placebo.

Lisa Swanson, MD, discusses the pathogenesis of atopic dermatitis and why she does not recommend elimination diets for her pediatric patients.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.

At SLEEP 2024, Badr presented on novel treatments for central sleep apnea like phrenic nerve stimulation.

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.

In this open-label extension trial presented at RAD 2024, the long-term safety and efficacy results of roflumilast cream in adults and children with eczema was highlighted.

Strnad explains key findings from research presented at the EASL Congress regarding noninvasive testing and biomarkers in AATD-LD based on phase 2 fazirsiran clinical trials.

Rosmarin discussed several treatments in development covered in his RAD 2024 presentation for the treatment of patients with eczema.

Study from RAD 2024 finds 36% higher risk of nonmelanoma skin cancer in patients with atopic dermatitis relative to matched controls.

In this interview, Chovatiya spoke about his second RAD 2024 talk regarding achieving remission with currently available eczema treatments.

Grandner highlights the importance of focusing on insomnia treatment for sleep-related anxiety—not anxiety treatment.

An analysis of data from the LIBERTY AD trial presented at RAD 2024 details the risk of infections observed with dupilumab use with up to 5 years of follow-up.

The new approval expands the treatment area by 4 times the previously approved area—from 25 cm2 to 100 cm2.

Improvements in multiple sign efficacy endpoints were observed in the full study population, with more pronounced effects in the TNFR1 genetic biomarker population.

A higher serum ferritin threshold could lead to better diagnosis and treatment of more women with iron deficiency.

This RAD 2024 interview featured a discussion of currently FDA-approved atopic dermatitis therapies and their comparisons.

Congly explains key findings from his cross-sectional study of costs associated with HBV treatment in patients on Medicaid and the economic impact of generic versus originator use.

This segment of Paller’s RAD 2024 interview covers tips for treating children with biologics as well as unmet needs of eczema patients and upcoming treatments.

An analysis of data from the NIH's All of Us program details the prevalence of fatigue among patients with pruritus among US patients.